MedTrace Logo

Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

NCT06150040 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-02-20

No results posted yet for this study

Summary

The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with Azacitidine and Venetoclax in patients with refractory acute myeloid leukemia after 2 cycles of Azacitidine and Venetoclax.

Conditions

  • Acute Myeloid Leukemia Refractory

Interventions

DRUG

NP137

IV infusion, 14mg/kg or 9mg/kg, every 2 weeks

DRUG

Azacitidine Injection

Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)

DRUG

Venetoclax

Orally, 70 mg, every day on Days 1-28

Sponsors & Collaborators

  • NETRIS Pharma

    collaborator INDUSTRY

  • Centre Leon Berard

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-11
Primary Completion
2025-02-18
Completion
2025-02-18

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06150040 on ClinicalTrials.gov